IL6 and non-small cell lung carcinoma: Similarly, other studies have shown that, at least in non-small cell lung carcinoma, increased IL-6 production (which is also upregulated in vMyx-hTNF/PBMC-treated animals) after anti-PD-L1/anti-PD-1 therapy was a potential predictor of positive outcome in patients.53